Cardiorenal Protective Effects of Year-Long Antihypertensive Therapy With a Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker in Spontaneously Hypertensive Rats

American Journal of Hypertension

Volumn 19, Issue 12, 2006, Pages 1233-1240

  Ishimitsu, Toshihiko ^a   Honda, Takeaki ^a   Ohta, Satoshi ^a   Akashiba, Akira ^a   Takahashi, Toshiaki ^a   Kameda, Tomoko ^a   Yoshii, Masayoshi ^a   Minami, Junichi ^a   Takahashi, Masaki ^a   Ono, Hidehiko ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

angiotensin converting enzyme inhibitor; calcium channel blocker; glomerular sclerosis; left ventricular hypertrophy; Spontaneously hypertensive rats

Indexed keywords

DRINKING WATER; HYDROXYPROLINE; NITRENDIPINE; QUINAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; ECHOCARDIOGRAPHY; GLOMERULOPATHY; HEART PROTECTION; HEART WEIGHT; HYPERTENSION; INJURY SCALE; KIDNEY INJURY; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; HEART RATE; HEART VENTRICLES; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MALE; NITRENDIPINE; ORGAN SIZE; PROTEINURIA; RATS; RATS, INBRED SHR; TETRAHYDROISOQUINOLINES; TIME FACTORS;

EID: 33845187183     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.05.019     Document Type: Article

References (30)

1. Dworkin L.D., Levin R.I., Benstein J.A., Parker M., Ullian M.E., Kim Y., and Feiner H.D. Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 259 (1990) F598-F604
2. Pu Q., Amiri F., Gannon P., and Schiffrin E.L. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats. J Hypertens 23 (2005) 401-409
3. Brilla C.G. Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovasc Res 46 (2000) 324-331
4. Wenzel U.O., Helmchen U., Schoeppe W., and Schwietzer G. Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Hypertension 23 (1994) 114-122
5. Dworkin L.D., Benstein J.A., Parker M., Tolbert E., and Feiner H.D. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 43 (1993) 808-814
6. Tornig J., Amann K., Ritz E., Nichols C., Zeier M., and Mall G. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7 (1996) 667-675
7. Ono Y., Ono H., Matsuoka H., Fujimori T., and Frohlich E.D. Apoptosis, coronary arterial remodeling, and myocardial infarction after nitric oxide inhibition in SHR. Hypertension 34 (1999) 609-616
8. Ono H., Saitoh M., Ono Y., Ishimitu T., and Matsuoka H. Imidapril improves L-NAME-exacerbated nephrosclerosis with TGF-beta 1 inhibition in spontaneously hypertensive rats. J Hypertens 22 (2004) 1389-1395
9. Yamori Y. Pathogenesis of spontaneous hypertension as a model for essential hypertension. Jpn Circ J 41 (1977) 259-266
10. Frohlich E.D., and Arthus C. Corcoran Memorial Lecture. Influence of nitric oxide and angiotensin II on renal involvement in hypertension. Hypertension 29 (1997) 188-193
11. Katayama S., Abe M., Inaba M., Itabashi A., and Ishii J. Effects of captopril or nitrendipine on left ventricular collagen or laminin B2 gene expression. Jpn Heart J 34 (1993) 773-783
12. Liu J.G., Xu L.P., Chu Z.X., Miao C.Y., and Su D.F. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens 21 (2003) 1961-1967
13. Shimizu G., Hirota Y., Kita Y., Kawamura K., Saito T., and Gaasch W.H. Left ventricular midwall mechanics in systemic arterial hypertension. Myocardial function is depressed in pressure-overload hypertrophy. Circulation 83 (1991) 1676-1684
14. Litwin S.E., Katz S.E., Morgan J.P., and Douglas P.S. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 89 (1994) 345-354
15. Hsu C.Y., Vittinghoff E., Lin F., and Shlipak M.G. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 141 (2004) 95-101
16. Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure. ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 112 (2005) 1825-1852
17. Fang J., and Alderman M.H. Trend of stroke hospitalization, United States, 1988-1997. Stroke 32 (2001) 2221-2226
18. Brewster U.C., Setaro J.F., and Perazella M.A. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326 (2003) 15-24
19. Struthers A.D., and MacDonald T.M. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 61 (2004) 663-670
20. Nakajima T., Yamada T., and Setoguchi M. Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats. J Cardiovasc Pharmacol 19 (1992) 102-107
21. Burlew B.S., and Weber K.T. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 27 (2002) 92-98
22. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., Leimberger J.D., Henis M., Edwards S., Zelenkofske S., Sellers M.A., and Califf R.M. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
23. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Yusuf S., and Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
24. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2897
25. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., Hua T., Laragh J., McInnes G.T., Mitchell L., Plat F., Schork A., Smith B., and Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
26. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
27. Brenner B.M., Lawler E.V., and Mackenzie H.S. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 49 (1996) 1774-1777
28. Romero J.C., Ruilope L.M., Bentley M.D., Fiksen-Olsen M.J., Lahera V., and Vidal M.J. Comparison of the effects of calcium antagonists and converting enzyme inhibitors on renal function under normal and hypertensive conditions. Am J Cardiol 62 (1988) 59G-68G
29. Raij L. Recommendations for the management of special populations: renal disease in diabetes. Am J Hypertens 16 (2003) 46S-49S
30. Jafar T.H., Schmid C.H., Landa M., Giatras I., Toto R., Remuzzi G., Maschio G., Brenner B.M., Kamper A., Zucchelli P., Becker G., Himmelmann A., Bannister K., Landais P., Shahinfar S., de Jong P.E., de Zeeuw D., Lau J., and Levey A.S. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135 (2001) 73-87